1-1, Nihonbashi-Honcho 2-chome
81 3 3278 2111
Industry: Drug Manufacturers—Specialty & Generic
|Mr. Christophe Weber||Pres, CEO & Representative Director||4.23M||N/A||1966|
|Mr. Constantine Saroukos||CFO & Representative Director||2.53M||N/A||1971|
|Dr. Andrew S. Plump||Pres of R&D and Representative Director||2.4M||N/A||1965|
|Dr. Seigo Izumo||Chair of Management Board||N/A||N/A||N/A|
|Mr. Haruhiko Hirate||Member of Management Board||N/A||N/A||1957|
|Salvatore Alesci||Member of Management Board and Head of R&D Global Science & Biomedical Policy||N/A||N/A||N/A|
|Norimasa Takeda||Chief Accounting Officer & Corp. Controller||N/A||N/A||N/A|
|Mr. Iwaaki Taniguchi||Sr. VP of Corp. Fin. & Controlling Department||N/A||N/A||N/A|
|Mr. Gabriele Ricci||Chief Data & Technology Officer||N/A||N/A||1978|
|Mr. Christopher David O'Reilly||Global Head of Investor Relations & Global Fin.||N/A||N/A||N/A|
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 30 May 2023 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 8; Compensation: 1.